BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012;47:421-426. [PMID: 22048256 DOI: 10.1007/s00535-011-0492-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Douhara A, Namisaki T, Moriya K, Kitade M, Kaji K, Kawaratani H, Takeda K, Okura Y, Takaya H, Noguchi R, Nishimura N, Seki K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Kubo T, Yoshiji H. Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. Oncol Lett 2017;14:3028-34. [PMID: 28927051 DOI: 10.3892/ol.2017.6489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
2 Nakano MM, Yamamoto A, Nishida N, Hamuro M, Hamamoto S, Jogo A, Sohgawa E, Kageyama K, Minami T, Miki Y. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol 2019;37:543-8. [DOI: 10.1007/s11604-019-00840-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Fang G, Wang J, Sun X, Xu R, Zhao X, Shao L, Sun C, Wang Y. LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2. Annals of Hepatology 2020;19:535-40. [DOI: 10.1016/j.aohep.2020.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Xie C, Song LB, Wu JH, Li J, Yun JP, Lai JM, Xie DY, Lin BL, Yuan YF, Li M. Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a. PLoS One. 2012;7:e40607. [PMID: 22815774 DOI: 10.1371/journal.pone.0040607] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
5 Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol 2017;23:42-50. [PMID: 28263954 DOI: 10.3350/cmh.2016.0058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Young S, Sanghvi T, Sharma S, Richardson C, Rubin N, Richards M, D'Souza D, Flanagan S, Golzarian J. Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma. Diagn Interv Imaging 2022:S2211-5684(22)00006-7. [PMID: 35115276 DOI: 10.1016/j.diii.2022.01.006] [Reference Citation Analysis]
7 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 10.9] [Reference Citation Analysis]
8 Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health. 2013;16:760-768. [PMID: 23947969 DOI: 10.1016/j.jval.2013.03.1630] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
9 Park S, Kim TS, Kang SH, Kim HB, Park JW, Kim SK. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization. Medicine (Baltimore) 2018;97:e12311. [PMID: 30212970 DOI: 10.1097/MD.0000000000012311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
10 Song YG, Shin SW, Cho SK, Choi D, Rhim H, Lee MW, Kim YS, Park KB, Park HS, Choo SW, Do YS, Choo IW, Hyun D. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. Acta Radiol 2015;56:70-7. [PMID: 24518688 DOI: 10.1177/0284185114520857] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
11 Langenbach MC, Vogl TJ, Said G, Scholtz JE, Hammerstingl R, Gruber-Rouh T. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2021. [PMID: 33481646 DOI: 10.1089/cbr.2020.4137] [Reference Citation Analysis]
12 Matsui Y, Horikawa M, Jahangiri Noudeh Y, Kaufman JA, Kolbeck KJ, Farsad K. Baseline Tumor Lipiodol Uptake after Transarterial Chemoembolization for Hepatocellular Carcinoma: Identification of a Threshold Value Predicting Tumor Recurrence. Radiol Oncol 2017;51:393-400. [PMID: 29333117 DOI: 10.1515/raon-2017-0030] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Lee SW, Lee TY, Cheng YC, Yen CL, Yang SS. The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Medicine (Baltimore) 2021;100:e26414. [PMID: 34190159 DOI: 10.1097/MD.0000000000026414] [Reference Citation Analysis]
14 Ueshima E, Nishiofuku H, Takaki H, Hirata Y, Kodama H, Tanaka T, Kichikawa K, Yamakado K, Okada T, Sofue K, Yamaguchi M, Sugimoto K, Murakami T. Hepatic Artery Embolization Induces the Local Overexpression of Transforming Growth Factor β1 in a Rat Hepatoma Model. Liver Cancer 2020;9:63-72. [PMID: 32071910 DOI: 10.1159/000502774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK; Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer 2020;20:483. [PMID: 32471447 DOI: 10.1186/s12885-020-06806-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol 2014; 20(22): 6995-7004 [PMID: 24944494 DOI: 10.3748/wjg.v20.i22.6995] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
17 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
18 Dioguardi Burgio M, Sartoris R, Libotean C, Zappa M, Sibert A, Vilgrain V, Ronot M. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging 2019;19:75. [PMID: 31730491 DOI: 10.1186/s40644-019-0260-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Ippolito D, Fior D, Bonaffini PA, Capraro C, Leni D, Corso R, Sironi S. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol. 2014;83:1665-1671. [PMID: 24962900 DOI: 10.1016/j.ejrad.2014.05.040] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
20 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Hassany M, Elsharkawy A, Maged A, Mehrez M, Asem N, Gomaa A, Mostafa Z, Abbas B, Soliman M, Esmat G. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol 2018;30:876-81. [PMID: 29727383 DOI: 10.1097/MEG.0000000000001152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
22 Mueller K, Fahrig R, Manhart M, Deuerling-zheng Y, Rosenberg J, Moore T, Ganguly A, Kothary N. Reproducibility of Parenchymal Blood Volume Measurements Using an Angiographic C-arm CT System. Academic Radiology 2016;23:1441-5. [DOI: 10.1016/j.acra.2016.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Lee TY, Lin CC, Chen CY, Wang TE, Lo GH, Chang CS, Chao Y. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial. Medicine (Baltimore). 2017;96:e7655. [PMID: 28906355 DOI: 10.1097/md.0000000000007655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
24 Zhang J, Jiang H, Xia W, Jiang Y, Tan X, Liu P, Jia H, Yang X, Shen G. Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival. Tumour Biol 2016;37:283-90. [PMID: 26201897 DOI: 10.1007/s13277-015-3771-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
25 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014; 20(3): 745-754 [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]